Literature DB >> 15960925

[Paralytic ileus due to vinorelbine].

Gaspar Esquerdo Galiana1, Hugo Briceño García, Cristina Llorca Ferrándiz, José Manuel Cervera Grau.   

Abstract

Intestinal obstruction is very common in cancer patients and occurs in 80% of cases with malignant aetiology. Hence, aggressive treatment is needed in most cases. The occlusion can be caused by luminal obstruction, paralysis of the intestinal muscle or carcinomatosis with mesentery involvement. The clinical case we present is that of a patient diagnosed as having lung cancer and who was admitted with paralytic ileus following treatment with vinorelbine; a vinca alkaloid whose main characteristic toxicities include neutropenia and peripheral neuropathy. Also, on rare occasions, the drug can cause paralysis of the ileum due to autonomic neuropathy. Hence, before administering aggressive treatment to an occlusive syndrome, cases that could benefit from conservative treatment should be ruled out.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15960925     DOI: 10.1007/bf02708755

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  6 in total

1.  Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study.

Authors:  M Baines; D J Oliver; R L Carter
Journal:  Lancet       Date:  1985-11-02       Impact factor: 79.321

2.  Neurotoxicity after chemotherapy with vinorelbine.

Authors:  F Lonardi; G Pavanato; V Ferrari; G Bonciarelli; A Jirillo; M Balli
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

3.  Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer.

Authors:  S L Blair; D Z Chu; R E Schwarz
Journal:  Ann Surg Oncol       Date:  2001-09       Impact factor: 5.344

Review 4.  Palliative management of malignant bowel obstruction.

Authors:  Carla Ripamonti; Eduardo Bruera
Journal:  Int J Gynecol Cancer       Date:  2002 Mar-Apr       Impact factor: 3.437

5.  Management of bowel obstruction in advanced and terminal cancer patients.

Authors:  C Ripamonti; F De Conno; V Ventafridda; B Rossi; M J Baines
Journal:  Ann Oncol       Date:  1993-01       Impact factor: 32.976

6.  Epirubicin/vinorelbine as first line therapy in metastatic breast cancer.

Authors:  E Baldini; C Tibaldi; F Chiavacci; M Di Lieto; L Fioretto; A Giallom-bardo; R Taviani; P Ghezzi; A Bolognini; P Conte
Journal:  Breast Cancer Res Treat       Date:  1998-05       Impact factor: 4.872

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.